Fosun, BioNTech Form $200 Million China JV to Make COVID-19 Vaccine
May 11, 2021 at 06:17 AM EDT
Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China . The JV will have capacity to manufacture 1 billion doses of the vaccine. Fosun will invest $100 million to build the facility for its 50% share of the JV, while BioNTech will contribute its proprietary manufacturing technology, which it values at $100 million. In March 2020, the two companies partnered China development of the COVID-19 vaccine in a $135 million deal. More details.... Share this with colleagues: // //